admin – Varizig

For U.S. Healthcare Professionals Only

About VARIZIG^®
- About VARIZIG^®
- About Varicella Zoster
Efficacy & Safety
Ordering
Resources
Contact Us

About VARIZIG^®
- About VARIZIG^®
- About Varicella Zoster
Efficacy & Safety
Ordering
Resources
Contact Us

Important Safety Information

VARIZIG^® contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity) reactions to human immune globulin preparations should not receive VARIZIG^®. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity may have an anaphylactoid reaction. Thrombotic events may occur during or following treatment with immune globulin products. Administer VARIZIG^® intramuscularly only. In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, only administer VARIZIG^® if the expected benefits outweigh the potential risks. Severe hypersensitivity reactions may occur following VARIZIG^® administration. In case of hypersensitivity, discontinue administration of VARIZIG^® immediately and provide appropriate treatment. Because VARIZIG^® is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent, and, theoretically, the Creutzfeldt-Jakob disease agent. The most serious adverse drug reactions observed in clinical trials for all subjects and patients include pyrexia, nausea, and vomiting. The most common adverse drug reactions observed in clinical trials for all subjects and patients were injection site pain, headache, chills, fatigue, rash, and nausea.

Please see full Prescribing Information for complete prescribing details. To report SUSPECTED ADVERSE REACTIONS, contact Kamada at pharmacovigilance@kamada.com or 1-(866)-916-0077 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

About VARIZIG^®
About Varicella Zoster
Efficacy & Safety
Ordering & Reimbursement
Resources
Contact Us

About VARIZIG^®
About Varicella Zoster
Efficacy & Safety
Ordering & Reimbursement
Resources
Contact Us

About VARIZIG^®
About Varicella Zoster

About VARIZIG^®
About Varicella Zoster

Efficacy & Safety
Ordering & Reimbursement

Efficacy & Safety
Ordering & Reimbursement

Resources
Contact Us

Resources
Contact Us

VARIZIG® [Varicella Zoster Immune Globulin (Human)] and all Kamada brand, product, service and feature names, logos, and slogansare trademarks or registered trademarks of Kamada in the United States and/or other countries. Copyright 2024 Kamada. All rights reserved.

Privacy Policy Terms of Use Contact Us

Kamada Inc., 221 River St, Hoboken, NJ 07030 Tel. 1-833-779-2614

Important Safety Information

VARIZIG^® contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity)

VARIZIG^® contains trace amounts of IgA. Individuals known to have anaphylactic or severe systemic (hypersensitivity) reactions to human immune globulin preparations should not receive VARIZIG^®. IgA-deficient patients with antibodies against IgA and a history of hypersensitivity may have an anaphylactoid reaction. Thrombotic events may occur during or following treatment with immune globulin products.